Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2004-7-14
pubmed:abstractText
While tumors of dendritic cell lineage may have overlapping histomorphologic features, most but not all cases can be classified using an immunohistochemical panel, including CD21, CD23, CD35, CD1a, and S-100. Based on observations that clusterin is expressed in benign follicular dendritic cells, clusterin expression in 32 dendritic cell tumors was evaluated. Diffuse strong staining for clusterin was seen in 12 of 12 follicular dendritic cell tumors. Two of these cases were negative for traditional markers (CD21, CD23, CD35); they were classified based on characteristic ultrastructural features. Three of 6 interdigitating dendritic cell tumors were negative for clusterin and 3 showed focal weak positivity. Clusterin staining in Langerhans cell histiocytosis ranged from negative (6 of 14) to weak/moderate (8 of 14). Follicular dendritic cell tumors behaved as benign tumors or low-grade sarcomas. Interdigitating dendritic cell tumors demonstrated a widely variable behavior, ranging from benign to rapidly fatal disease. Based on this initial study, strong clusterin staining supports a diagnosis of follicular dendritic cell tumor. Thus, staining for clusterin is useful in classification of dendritic cell tumors, particularly when the more common markers of follicular dendritic cells are not expressed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0147-5185
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
988-98
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15252304-Adolescent, pubmed-meshheading:15252304-Adult, pubmed-meshheading:15252304-Aged, pubmed-meshheading:15252304-Aged, 80 and over, pubmed-meshheading:15252304-Cell Count, pubmed-meshheading:15252304-Clusterin, pubmed-meshheading:15252304-Combined Modality Therapy, pubmed-meshheading:15252304-Dendritic Cells, Follicular, pubmed-meshheading:15252304-Female, pubmed-meshheading:15252304-Glycoproteins, pubmed-meshheading:15252304-Histiocytosis, Langerhans-Cell, pubmed-meshheading:15252304-Humans, pubmed-meshheading:15252304-Immunohistochemistry, pubmed-meshheading:15252304-Lymph Nodes, pubmed-meshheading:15252304-Male, pubmed-meshheading:15252304-Middle Aged, pubmed-meshheading:15252304-Molecular Chaperones, pubmed-meshheading:15252304-Neoplasm Proteins, pubmed-meshheading:15252304-Sarcoma, pubmed-meshheading:15252304-Tumor Markers, Biological
pubmed:year
2004
pubmed:articleTitle
Clusterin expression distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms: report of a novel follicular dendritic cell marker and clinicopathologic data on 12 additional follicular dendritic cell tumors and 6 additional interdigitating dendritic cell tumors.
pubmed:affiliation
Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't